Shareholders of Capricor Therapeutics Urged to Act Ahead of Lead Plaintiff Deadline

Capricor Therapeutics Shareholder Class Action Update

Recently, SueWallSt has informed investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a significant development regarding a class action lawsuit. This case pertains to shareholders who bought securities between December 17, 2025 and July 26, 2026. In this complex legal matter, claims have been made suggesting that the company misled investors by presenting statistical results that were not only exaggerated but also supported by an altered analysis plan that had not received regulatory approval.

Chronology of Events

For shareholders and potential stakeholders, understanding the timeline of the events leading to this lawsuit is essential. The timeline begins with the announcement of promising results from the Phase 3 HOPE-3 study, where Capricor claimed the findings were statistically significant. However, critical information regarding the methodological adjustments to the statistical analysis plan (SAP) was addressed only later, raising questions about the integrity of those claims.

1. November 24, 2025: The final statistical analysis plan was dated just a day before the trial data was unblinded, and it was later revealed that this plan was not submitted for FDA approval.
2. December 17, 2025: The class period commenced as the company touted the HOPE-3 topline results, marking them as statistically significant.
3. January 20, 2026: Capricor shared a regulatory update which continued to affirm the efficacy of the HOPE-3 study, portraying their improvements impressively.
4. March 10, 2026: The FDA lifted a Complete Response Letter, and by this time, excitement surged around the potential drug.
5. July 27, 2026: On receiving FDA briefing documents, the tone shifted dramatically as they claimed that the study did not meet pre-specified endpoints, leading to a significant drop in share price.
6. July 30, 2026: An advisory committee vote concluded, showing opposition against supporting the efficacy of the drug, which further contributed to the plummeting stock price.

Impact on Shareholders

For those who invested in Capricor during this tumultuous period, the implications could be severe. The lawsuit alleges that Capricor made misleading statements which inflated share prices and ultimately led to substantial losses when the truth was finally revealed. The stock fell nearly 78.7%, equating to a significant loss for investors who had believed in the company’s claims.

Joseph E. Levi, Esq., a representative for SueWallSt, emphasizes the crucial nature of timely disclosures in maintaining fair market practices. He highlights that the heart of the issue remains unanswered: When did Capricor become aware of the changes to the SAP that were not agreed upon by the FDA, and why were those details not disclosed to shareholders promptly?

What Should Investors Do Next?

Investors who purchased Capricor securities during the specified period should take immediate action. The deadline to apply for lead plaintiff status is September 28, 2026. Documentation from brokerage accounts will be necessary; this should include details about share quantities, purchase dates, and prices paid. For no-cost, no-obligation evaluations, shareholders can contact SueWallSt for guidance on potential eligibility for recovery.

Furthermore, previously sold shares do not exclude an investor’s eligibility; as long as they bought shares during the class period, they may still seek restitution. Participation in such securities lawsuits typically involves no upfront costs, as fees are contingent upon successful recoveries through the legal process.

Conclusion

The stakes in the Capricor Therapeutics case are high, as the actions taken by the company and the subsequent declarations by the FDA have prompted serious concerns over investor rights and market integrity. Those affected are strongly encouraged to connect with legal representatives to discuss their options and ascertain their eligibility. The timeline of the lawsuit will undoubtedly unfold further as more developments occur.

For more information, shareholders can reach out to Levi Korsinsky LLP at (888) SueWallSt or via email for a detailed assessment of their situation.